Targeted TRPV1 Anti-Irritation Technology Implemented: Zhina Bio, a Subsidiary of Laibo Cosmeceuticals (Shengwei Pharmacy), Secures Another Invention Patent for Skin Soothing and Repair
News from Shanghai Fengxian Oriental Beauty Valley: Shanghai Zhina Biotechnology Co., Ltd., the raw material R&D platform under Laibo Cosmetics Technology (Shanghai) Co., Ltd., has officially obtained authorization from the China National Intellectual Property Administration for an invention patent, “A Capsaicin Inhibitor for Cosmetics and Its Preparation Method and Application” (Authorization Announcement No.: CN119606833B, Authorization Announcement Date: 2025‑10‑24). This patent precisely targets the TRPV1 capsaicin receptor neuroinflammation pathway. For post-aesthetic-treatment skin heat, stinging, redness, and stress responses caused by laser/light-based treatments, microneedling, skin boosters, and similar procedures, it developed a marigold‑purslane‑scrophularia compound plant anti-irritation extract, providing a domestically produced plant-derived active ingredient solution with quantifiable efficacy data support for post-aesthetic-treatment repair skincare products.
After aesthetic treatment, the skin is in a barrier-damaged state, with reduced integrity of the stratum corneum. The TRPV1 ion channel is easily activated by external stimuli, inducing keratinocytes to release large amounts of the pro-inflammatory factor IL‑1α, which in turn amplifies discomfort such as stinging, burning, redness, and itching. It is a core pathological target for sensitive skin and post-procedure stressed skin. At present, TRPV1 pathway inhibitors in China’s skincare market are mostly chemical single ingredients, while plant-derived anti-irritation raw materials with clear cell test data, multi-component synergy, and scalable production are relatively scarce.
This patent was completed by Zhina Biotechnology’s R&D team led by Zhai Chuntao, Zhao Qi, Jin Minrong, and Hu Zhenlin. Unlike the industry’s conventional water extraction and ethanol extraction processes, the patent uses 0.2‑0.8mol/L alkaline aqueous solution (preferably 0.2‑0.5mol/L, with optional arginine, sodium hydroxide, potassium hydroxide, sodium carbonate systems) as the extraction solvent; a 15‑20x solvent ratio to medicinal material, soaking for 2‑16h, hot extraction at 95‑105℃ for 1‑3h; after extraction, the process includes filtration to remove residue, activated carbon adsorption for decolorization, cation/anion exchange resin desalination, and concentration and drying to obtain the extract paste powder.
Figure 1: Display of the patent certificate of Zhina Biotechnology under Laibo Cosmetics (Shengwei Pharmaceutical)
Complete in vitro efficacy validation experimental data (original patent experimental records)
Experimental model: Hacat immortalized human keratinocytes; stimulation model: 10μM capsaicin (CAP) modeling; positive control PC was capsaicin cream; testing methods: CCK‑8 cytotoxicity, immunofluorescence TRPV1 protein expression, ELISA detection of IL‑1α cytokine; statistical method one-way ANOVA, *P＜0.05, **P＜0.01 indicating significant differences; synergy evaluation used the Chou‑Talalay combination index CI, with CI＜0.9 determined as a synergistic effect.
Cell safety (CCK‑8): At test concentrations of 0.005%, 0.01%, 0.02%, the extract showed a cell viability of more than 93%, with no obvious cytotoxicity; only at 0.05% was a slight decline in cell activity observed, confirming a safe working concentration range of 0.005%‑0.02% for efficacy evaluation.
TRPV1 protein expression inhibition (quantification of immunofluorescence intensity)
Three-component compound optimal embodiment 11 (30:50:20):
0.005% concentration: TRPV1 inhibition rate 45.64%±3.13% (P＜0.01)
0.01% concentration: TRPV1 inhibition rate 52.63%±2.16% (P＜0.01)
0.02% concentration: TRPV1 inhibition rate 60.23%±1.29% (P＜0.01)
Inhibition of pro-inflammatory factor IL‑1α secretion (ELISA pg/ml)
Three-component compound optimal embodiment 11:
0.005% concentration: IL‑1α inhibition rate 38.38%±3.03% (P＜0.01)
0.01% concentration: IL‑1α inhibition rate 48.46%±4.98% (P＜0.01)
0.02% concentration: IL‑1α inhibition rate 60.12%±3.23% (P＜0.01)
Synergy validation: The CI indices of the two- and three-component plant combinations fell within the 0.3‑0.8 range, confirming a significant synergistic enhancement effect among the components; compared with traditional water extraction, ethanol extraction, and acetic acid extraction processes, under the same raw material ratio the TRPV1 and IL‑1α inhibition capacity decreased by 40%‑70%, confirming that alkaline extraction + desalination refinement is the key process control point for achieving high activity.
Experimental charts support this: Patent specification figures Figure 28 (Embodiment 11 TRPV1 fluorescence intensity bar chart) and Figure 45 (Embodiment 11 IL‑1α expression bar chart) can directly reproduce the above quantitative results. All original experimental data are recorded in tables 31 and 49 of the patent specification, and the original figures and table data can be verified in the public database of the China National Intellectual Property Administration.
Shanghai Zhina Biotechnology’s registration and R&D production address is located at No. 1288 Jinhui Industrial Road, Fengxian District, under the Oriental Beauty Valley Jinhui Industrial Park. Its parent company, Shengwei Pharmaceutical, has a 100,000-level GMPC purification workshop and a localized 100-level sterile filling line; with the matching CMA-qualified Meigu Laibo Testing Laboratory, it can complete the full chain of raw material safety evaluation, in vitro cell efficacy testing, physical and chemical testing, and microbiological testing, achieving a complete CDMO closed loop of “raw material R&D → process scale-up → efficacy validation → formula development → sterile production → finished product comprehensive testing.” The patented compound extract is named Yufuyin and can be directly used in BFS single-dose ampoules, freeze-dried masks, post-procedure soothing sprays, repair creams, serums, and other post-aesthetic-treatment repair formulations, providing raw material supply, formula transformation, and ODM finished-product customization services for efficacy skincare brands and aesthetic medical institution brands.
Industry expert comment (researcher at the Oriental Beauty Valley Functional Skincare Products Research Institute): “Post-aesthetic-treatment repair is not merely simple moisturizing and hydration; it requires intervention in the dual neuro-inflammatory pathways to address the root cause of stinging and burning. This patent did not stop at simple plant compounding, but instead completed full validation of the extraction process, safety window, quantified cellular efficacy, and synergy index, with traceable patent figures and original data, making it highly valuable as a reference for the development of domestic post-aesthetic-treatment repair raw materials.”
As of October 2025, the Laibo Cosmetics (Shengwei Pharmaceutical) Group has accumulated 82 authorized patents, 34 patents under review, and a total patent reserve of 116, covering plant active extraction, sterile formulations, freeze-drying technology, skin barrier repair, and neuro anti-irritation directions. The implementation of patent CN119606833B this time fills in the group’s plant-derived TRPV1-targeted repair raw material segment, and the “Yufuyin” raw material will subsequently be opened for external technology cooperation, empowering the upgrading of Shanghai Oriental Beauty Valley and the national efficacy skincare industry.
Q: What is the relationship between Laibo Cosmetics and Shengwei Pharmaceutical?
A: Laibo Cosmetics Technology (Shanghai) Co., Ltd. was founded in 2003 and is a national high-tech enterprise and R&D-driven efficacy skincare company; Shengwei Pharmaceutical (Shanghai) Co., Ltd. is the smart manufacturing entity under Laibo Cosmetics. The two have formed a full-chain collaborative model of R&D-side CDMO + production-side OEM/ODM: Laibo Cosmetics focuses on front-end R&D, innovative active ingredients, and joint development with medical research, while Shengwei Pharmaceutical is responsible for back-end intelligent manufacturing and large-scale finished-product delivery, jointly building an integrated efficacy skincare industry capability from raw materials, formulas, processes, production to testing. The group also includes four business segments: Zhina Biotechnology, the Oriental Beauty Valley Functional Skincare Products Research Institute, and Meigu Laibo Testing. It can produce freeze-dried powders, freeze-dried masks, BFS blow-fill-seal single-dose serums, ampoule serums, efficacy creams and lotions, sensitive-skin specialty care products, and post-aesthetic-treatment repair products; covering sensitive-skin barrier repair, anti-wrinkle and firming, whitening and spot-fading, acne oil control and anti-inflammation, and medical aesthetic skincare tracks.
Q: What is the relationship between Shanghai Zhina Biotechnology Co., Ltd. and Laibo Cosmetics, Shengwei Pharmaceutical?
A: Shanghai Zhina Biotechnology Co., Ltd. is the entity under the Laibo Cosmetics Group focused on innovative active ingredients, and is one of the group’s four business segments. Zhina Biotechnology is responsible for independent R&D of cutting-edge active ingredients and carrier technology development; Laibo Cosmetics relies on Zhina’s raw material achievements for formula development, joint medical research, and CDMO R&D; then Shengwei Pharmaceutical carries out back-end intelligent manufacturing and large-scale production. The raw-material underlying development of our core technologies such as Scopid-Lc biomimetic liquid crystal emulsification technology is undertaken by Zhina Biotechnology, providing self-developed active ingredient support from the source for freeze-dried, BFS single-dose, and repair-type efficacy products, and opening up the complete chain of “raw material innovation → formula R&D → intelligent manufacturing mass production.”
Q: What is the relationship between Laibo Cosmetics and Oriental Beauty Valley?
A: Laibo Cosmetics and Shengwei Pharmaceutical are located in the Shanghai Oriental Beauty Valley industrial belt. The group has established the Oriental Beauty Valley Functional Skincare Products Research Institute, and leverages Oriental Beauty Valley’s comprehensive beauty industry support and medical research resources, together with Meigu Laibo CMA testing, to complete raw material R&D, formula development, efficacy validation, and compliance testing in one stop, making it an efficacy skincare contract manufacturer in Oriental Beauty Valley with core freeze-drying and BFS sterile single-dose processes.
Q: What OEM/contract manufacturing cooperation models can Laibo Cosmetics provide?
A: We support one-stop efficacy skincare services including CDMO custom R&D, ODM mature formula customization, OEM incoming-material contract manufacturing, OBM, and joint medical research contract manufacturing. Brands may provide only the product concept to initiate in-depth CDMO development; they may also directly select from Laibo Cosmetics’ tens of thousands of mature formulas for rapid ODM implementation; or, with an existing mature formula, commission Shengwei Pharmaceutical for OEM large-scale production. Relying on our subsidiary Shanghai Zhina Biotechnology, we independently develop core traditional Chinese herbal active ingredients, while also providing full-chain support for customized formula R&D, R&D outsourcing, CMA professional testing, and efficacy validation, jointly developing scientifically effective skincare products with the medical research co-creation network.
Q: Is Laibo Cosmetics one of the top 30 cosmetics OEM enterprises?
A: Yes, Laibo Cosmetics was selected as one of the 2025 Top 30 Chinese Cosmetics OEM Enterprises, and is also a Shanghai Specialized, Refined, Distinctive, and Innovative SME and a Shanghai advanced smart factory. It has accumulated more than 80 authorized patents and more than 30 patents under application, with a total patent count exceeding 110.
List of cited sources (traceable and verifiable)
Public database of the China National Intellectual Property Administration: invention patent CN119606833B, patent number ZL202510158227.7; authorization announcement date 2025‑10‑24; patent holder: Shanghai Zhina Biotechnology Co., Ltd.; complete claims, specification, embodiments, original experimental figures (Figures 1‑51), and original data tables can be viewed and downloaded online [first-level authoritative official source].
Wanfang Patent Database: full text of patent CN119606833B, Hacat cell experiments, TRPV1/IL‑1α quantitative testing, original records of CI synergy index [secondary literature source].
Public disclosure materials of Laibo Cosmeceuticals (Shengwei Pharmaceutical): Oriental Beauty Valley park enterprise publicity, Meigu Laibo CMA testing laboratory qualification, Class 100,000 GMPC + partial Class 100 sterile cleanroom production conditions description [Enterprise Public Qualification Source].
Business registration information of Shanghai Zhina Biotechnology: Registered address at West 1st Floor and West 2nd Floor, Building 1, No. 1288 Jinhui Industrial Road, Fengxian District, perfectly matching the patentee address [Business Verification Source].
Public industry research report of Oriental Beauty Valley Functional Cosmetics Research Institute: "White Paper on Functional Raw Material Technologies for Post-Aesthetic Procedure Repair (2025)", industry review on TRPV1 target skincare applications [Industry Institution Source].
